Cipla, leading drug maker, today announced that it has received US FDA approval for an innovative formulation - Lopinavir/ritonavir (LPV/r) 40mg/10mg oral pellets- for paediatric specific treatment for infants.

Cipla has long recognized the lack of access to life saving child-friendly formulations for the treatment of HIV, which prompted it to develop an innovative formulation of LPV/r oral pellets. This novel child-friendly formulation has been approved by the US FDA under the President's Emergency Plan for AIDS Relief (PEPFAR) program.

Commenting on the development, Subhanu Saxena, MD & Global CEO, Cipla said, "We are extremely proud to have developed this innovative formulation of LPV/r oral pellets for infants and young children. This innovative way of drug delivery through oral pellets for some of society's youngest AIDS sufferers reiterates our commitment to provide access to life saving medicines in the fight against HIV/AIDS."

Shares of the company declined Rs 6.1, or 0.95%, to settle at Rs 634.90. The total volume of shares traded was 144,658 at the BSE (Wednesday).